The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of BPX-201 vaccine plus AP1903 for chemo-naive metastatic castrate-resistant prostate cancer (mCRPC).
Guru Sonpavde
Research Funding - Bellicum Pharmaceuticals
Thomas E. Hutson
Research Funding - Bellicum Pharmaceuticals
Graeme Bolger
Research Funding - Bellicum Pharmaceuticals
Lawrence Fong
No relevant relationships to disclose
Eric Jay Small
No relevant relationships to disclose
David M. Spencer
Employment or Leadership Position - Bellicum Pharmaceuticals
Stock Ownership - Bellicum Pharmaceuticals
Annemarie Moseley
Employment or Leadership Position - Bellicum Pharmaceuticals
Stock Ownership - Bellicum Pharmaceuticals
Kevin Mark Slawin
Employment or Leadership Position - Bellicum Pharmaceuticals
Consultant or Advisory Role - Bellicum Pharmaceuticals
Stock Ownership - Bellicum Pharmaceuticals